Literature DB >> 10706701

Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy.

I Narvaiza1, G Mazzolini, M Barajas, M Duarte, M Zaratiegui, C Qian, I Melero, J Prieto.   

Abstract

We have constructed a recombinant defective adenovirus that expresses functional murine IFN-gamma-inducible protein-10 (IP-10) chemokine (AdCMVIP-10). Injection of AdCMVIP-10 into s.c. tumor nodules derived from the CT26 murine colorectal adenocarcinoma cell line displayed some antitumor activity but it was not curative in most cases. Previous studies have shown that injection of similar s. c. CT26 tumor nodules with adenovirus-encoding IL-12 (AdCMVIL-12) induces tumor regression in nearly 70% of cases in association with generation of antitumor CTL activity. AdCMVIP-10 synergizes with the antitumor effect of suboptimal doses of AdCMVIL-12, reaching 100% of tumor eradication not only against injected, but also against distant noninjected tumor nodules. Colocalization of both adenoviruses at the same tumor nodule was required for the local and distant therapeutic effects. Importantly, intratumoral gene transfer with IL-12 and IP-10 generated a powerful tumor-specific CTL response in a synergistic fashion, while both CD4 and CD8 T cells appeared in the infiltrate of regressing tumors. Moreover, the antitumor activity of IP-10 plus IL-12 combined gene therapy was greatly diminished by simultaneous in vivo depletion of CD4+ and CD8+ T cells but was largely unaffected by single depletion of each T cell subset. An important role for NK cells was also suggested by asialo GM1 depletion experiments. From a clinical point of view, the effects of IP-10 permit one to lower the required gene transfer level of IL-12, thus preventing dose-dependent IL-12-mediated toxicity while improving the therapeutic efficacy of the elicited antitumor response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706701     DOI: 10.4049/jimmunol.164.6.3112

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

Review 1.  Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies.

Authors:  V Schmitz; C Qian; J Ruiz; B Sangro; I Melero; G Mazzolini; I Narvaiza; J Prieto
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

Review 2.  The promise of gene therapy in gastrointestinal and liver diseases.

Authors:  J Prieto; M Herraiz; B Sangro; C Qian; G Mazzolini; I Melero; J Ruiz
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

3.  The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10.

Authors:  Keiji Tanese; Elizabeth A Grimm; Suhendan Ekmekcioglu
Journal:  Int J Cancer       Date:  2011-10-23       Impact factor: 7.396

Review 4.  Gene therapy: regulations, ethics and its practicalities in liver disease.

Authors:  Xi Jin; Yi-Da Yang; You-Ming Li
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

Review 5.  CXCR3 ligands: redundant, collaborative and antagonistic functions.

Authors:  Joanna R Groom; Andrew D Luster
Journal:  Immunol Cell Biol       Date:  2011-01-11       Impact factor: 5.126

6.  A combination of plasmid DNAs encoding murine fetal liver kinase 1 extracellular domain, murine interleukin-12, and murine interferon-gamma inducible protein-10 leads to tumor regression and survival in melanoma-bearing mice.

Authors:  Kristin Ladell; Jochen Heinrich; Marc Schweneker; Karin Moelling
Journal:  J Mol Med (Berl)       Date:  2003-04-04       Impact factor: 4.599

7.  Construction of a regulable gene therapy vector targeting for hepatocellular carcinoma.

Authors:  Shao-Ying Lu; Yan-Fang Sui; Zeng-Shan Li; Cheng-En Pan; Jing Ye; Wen-Yong Wang
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

Review 8.  Chemokines and their receptors play important roles in the development of hepatocellular carcinoma.

Authors:  Chun-Min Liang; Long Chen; Heng Hu; Hui-Ying Ma; Ling-Ling Gao; Jie Qin; Cui-Ping Zhong
Journal:  World J Hepatol       Date:  2015-06-08

Review 9.  Immunotherapy and immunoescape in colorectal cancer.

Authors:  Guillermo Mazzolini; Oihana Murillo; Catalina Atorrasagasti; Juan Dubrot; Iñigo Tirapu; Miguel Rizzo; Ainhoa Arina; Carlos Alfaro; Arantza Azpilicueta; Carmen Berasain; José L Perez-Gracia; Alvaro Gonzalez; Ignacio Melero
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

10.  Electroporation driven delivery of both an IL-12 expressing plasmid and cisplatin synergizes to inhibit B16 melanoma tumor growth through an NK cell mediated tumor killing mechanism.

Authors:  Ha Kim; Jeong-Im Sin
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.